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cabazitaxel, sipuleucel‑T, zoledronic acid, and 
radium‑22312–17 are welcome additions to the 
oncological‑urological armamentarium but 
after an initial response, resistance to most of 
these agents appears to develop.
Consequently, in our view, synthetic 
antagonistic analogs of peptides such as growth 
hormone‑releasing hormone (GHRH), LHRH, 
bombesin/gastrin releasing peptide (BN/GRP) 
that inhibit growth factors such as epidermal 
growth factor, vascular endothelial growth 
factor, insulin‑like growth factor‑I, II or analogs 
with cytotoxic moieties, which can target 
receptors on tumors, must be developed.8–10,18–20
As we know, therapies for metastatic 
hormone‑sensitive prostate cancer, as 
introduced by Huggins and Hodges21 and others 
include: orchiectomy, estrogens, adrenalectomy, 
corticosteroids, hypophysectomy, and 
anti‑androgens. Each can induce palliation in 
advanced prostate cancer; however, each has 
its pros and cons, morbidity and mortality, and 
limited long‑term efficacy. Our laboratory many 
years ago introduced LHRH agonists, which in 
chronic application downregulate pituitary 
LHRH receptors. In turn, this downregulation 
of LHRH receptors leads to an inhibition of 
the secretion of luteinizing hormone  (LH) 
and follicle‑stimulating hormone  (FSH), 
producing a suppression of androgen and 
estrogen levels in blood.1,7–10,22 The treatment of 
patients with prostate cancer has been greatly 
facilitated by the introduction of sustained 
delivery systems10,22 as the administration of 
microcapsules containing the agonist can be 
performed only every 3–6 months.
Following elucidation of the effects 
of LHRH agonists on prostate cancer and 
recognition of its associated effects, we turned 
our attention to LHRH antagonists. We and 
others synthesized antagonists of LHRH that 
It is a pleasure to contribute our presentation at the International Prostate Forum of the 
Annual Meeting of the American Urological 
Association (AUA) to this special issue of the 
Asian Journal of Andrology.
We are gratif ied that the method 
developed in our laboratories1 based on 
agonistic analogs of hypothalamic luteinizing 
hormone‑releasing hormone  (LHRH), also 
called gonadotropin‑releasing hormone, 
which was discovered and characterized by 
one of us  (AVS) in the 1970s,2–6 has been 
used since the early 1980s for the treatment 
of hormone‑dependent prostate cancer.7–11 
Since that time our laboratory has been 
trying to develop therapies for relapsed 
androgen‑independent, castration‑resistant 
prostate cancer (CRPC). These new therapies are 
also based on various analogs of hypothalamic 
hormones and are sorely needed when the 
patients with hormone‑dependent prostate 
cancer undergo loss of effect of androgen 
deprivation therapy and relapse. New drugs 
such as abiraterone, enzalutamide (MDV 3100), 
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block pituitary receptors for LHRH and produce 
an immediate cessation of secretion of LH, FSH 
and sex steroids.8–10 Early LHRH antagonists 
had some in edematogenic activities due to 
histamine release. In the LHRH antagonist, 
cetrorelix, developed by us, these activities were 
greatly reduced, and it was possible to carry out 
clinical studies in patients with prostate cancer 
and benign prostatic hyperplasia.8–10,23 Modern 
LHRH antagonist, degarelix, developed by 
Ferring, is the current drug of choice in this 
category.24–27 Degarelix has no serious adverse 
effects and avoids the flare phenomenon of 
LHRH agonists. Degarelix provides fast and 
effective control of testosterone, prostate 
specific antigen, LH, and FSH levels. It produces 
lower FSH levels than leuprolide, eliminates 
microsurges of testosterone, and leads to fewer 
cardiovascular and metabolic consequences 
than the LHRH agonists.24–27
Luteinizing hormone‑releasing hormone 
analogs provide effective palliative therapy for 
patients with advanced prostate carcinomas 
resulting in objective stable disease, partial 
remission and occasionally long‑term complete 
remission.8,9 However, all hormonal therapies 
aimed at androgen deprivation, including 
orchiectomy, anti‑androgens, LHRH agonists 
or antagonists, with or without anti‑androgens, 
usually provide remissions of only limited 
duration.8,9 Most patients who live long 
enough with advanced prostatic carcinoma 
relapse. The prognosis of these patients with 
androgen‑independent prostate cancer is very 
poor.8,9 The latest therapeutic drugs for prostate 
cancer, like abiraterone, extend the survival only 
by a few months.12,15,16
Continuing our studies, it became clear 
that some effects of LHRH analogs are 
exerted directly, rather than indirectly, on 
prostate cancer cells.8–10,28 We were able to 
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demonstrate the presence of high levels 
of receptors for LHRH, BN/GRP, and 
somatostatin, as well as mRNAs for their 
receptor subtypes, in human prostate cancer 
specimens.8–10,28 In experimental studies on 
human prostate cancer lines xenografted 
into nude mice, analogs of LHRH,10 analogs 
of somatostatin,29 and analogs of GRP30 
each inhibited prostate tumors growth and 
in  vitro reduced their proliferation.8–10,28 In 
vitro effects demonstrated a direct effect 
of these analogs on tumors.10 Following 
the example with Estracyt  (estramustine) 
consisting of nitrogen mustard coupled to 
carrier estrogen, we developed cytotoxic 
analogs of LHRH, somatostatin, and GRP 
which actively target respective receptors 
on prostate cancers.18–20,31–37 Thus, we have 
synthesized a targeted cytotoxic LHRH analog, 
denoted AN‑152  (commercially AEZS‑108, 
zoptarelin‑doxorubicin), which combines a 
D‑Lys‑6 LHRH agonist moiety  (necessary 
for binding to LHRH receptors on cancer cell 
surfaces) with the cytotoxic doxorubicin.19 
This analog delivers doxorubicin to only 
those cells with LHRH receptors on the cell 
membrane, thus avoiding cytotoxic side effects 
in normal cells. We found that after binding 
to LHRH receptors, AN‑152  (AEZS‑108) is 
internalized into the tumor cells.18,19,32,37
AN‑152 (AEZS‑108) was extensively tested 
in  vitro and also in  vivo in nude mice with 
xenografted human cancer lines expressing 
LHRH receptors.8,9,37 This drug inhibited the 
growth of a wide range of carcinomas (including 
k i d ne y,  pro s t ate ,  u rot he l iu m )  and 
sarcomas. These included DU‑145 human 
androgen‑independent prostate cancer as well 
as HT‑1376, J82, RT‑4 and HT‑1197 bladder 
cancer lines.8,9,37–39 The administration of 
AN‑152  (AEZS‑108) produced a powerful 
inhibition of tumor growth, greater than that 
induced by doxorubicin alone. The hybrid was 
found to be more efficacious and less toxic than 
doxorubicin.37 These studies were followed by 
Phase I and II human trials in women with 
endometrial and ovarian cancer expressing 
LHRH receptors.40,41
Dose escalation studies established that 
the maximum tolerated dose of AEZS‑108 is 
267  mg m−2. Dose‑limiting leukopenia and 
neutropenia were observed at the highest 
dose.40 Liu, Pinski et  al. also subjected 
AN‑152  (AEZS‑108) to Phase II trials in 
patients with CPRC resistant to taxane.42 
AEZS‑108 is currently in Phase III trials in 
USA and Europe in women with endometrial 
cancer. We have great expectations for it.
Another class of new and important 
antitumor peptides that could inhibit CRPC 
consists of antagonists of GHRH.43–46 The story 
behind these compounds is most interesting. 
One of us (AVS) was among the investigators 
who discovered GHRH in hypothalami of 
animals in the 1960s.43 Because only extremely 
small quantities of GHRH are present in 
the hypothalamus, it was not possible to 
characterize GHRH structurally until the early 
1980s.43 At that time, the clinicians became 
aware of cases of paraneoplastic acromegaly 
in some patients with pancreatic carcinoma. 
These tumors were actually producing GHRH, 
which then induced GH release from the 
pituitary. Thus, GHRH can be produced by 
tumors themselves, and it thus functions in 
an autocrine/paracrine fashion as a growth 
factor. Samples of these tumors were used 
for the isolation and structural elucidation of 
GHRH, which was then synthesized.43–46 Over 
the past 30 years, we have been investigating 
the role of GHRH in tumor growth and found 
that many tumors produced GHRH and 
had GHRH receptors.43–46 We determined 
that human prostate cancer specimens 
and human prostatic cell lines express 
GHRH and GHRH receptors.47 We also 
demonstrated the expression of splice variants 
of these receptors.47–49 This presence of 
GHRH receptors provides the basis for a new 
approach to the treatment of CRPC based 
on antagonists of GHRH.8,9,43 Thus, over 
the past 20  years we produced nearly 2000 
synthetic antagonistic analogs of GHRH, 
with each step improving their potency 
and half‑life.43–46,50 We substituted some of 
the natural  (coded) L‑amino acids in the 
N‑terminal 29 amino acid sequence of GHRH 
that has all the biological activity either with 
their “D” isomers or with totally synthetic 
amino acids.43–46,50 The structure of one of our 
GHRH antagonists, MIA‑602, the one we have 
chosen for clinical development, is shown in 
Table  1. We have found that these GHRH 
antagonists can block the growth of over 20 
different human tumor types, as exemplified 
by over 60 human cancer cell lines xenografted 
into nude mice.43–46,51–69 We showed that 
MIA‑602 and our other GHRH antagonists 
inhibited growth of PC‑3 and 22Rv1 human 
androgen‑independent prostate cancer cell 
lines and also hormone‑dependent prostate 
cancer lines.58–62 Our GHRH antagonists also 
suppressed prostate, kidney, urothelial, breast, 
triple‑negative breast, ovary, astrocytoma, 
melanoma, ENT tumors,  esophagus, 
stomach, colon, lung, adrenal cortical, 
pheochromocytoma, uterus, osteosarcomas 
and multiple lymphoma types. In addition 
to their inherent effects on cancer, we found 
that the GHRH antagonists also potentiated 
the effects of cytotoxic chemotherapy without 
enhancing the toxicity!70
The side effect/toxicity profile of GHRH 
analogs is minimal. Similarly, LHRH agonists 
and antagonists also have little or no toxicity, 
and it is really their anti‑androgenic effect, not 
the drugs themselves that cause some adverse 
effects.71,72
P E R S P E C T I V E S  F O R  T H E 
IMPROVEMENT OF THERAPY FOR 
CASTRATION-RESISTANT PROSTATE 
CANCER
Novel drugs are required for the treatment of 
CRPC. The best option may not be the agents 
that target androgen receptors or compounds 
which inhibit enzymes involved in androgen 
biosynthesis. This is because the androgen 
deprivation created by these compounds 
can be overcome by mutations in androgen 
receptors, the appearance of splice variants 
of these receptors or alternate biochemical 
pathways.
The use of currently available cytotoxic 
analogs of LHRH, or somatostatin that can 
be targeted to prostate cancers may lead to 
an improvement in the treatment of CRPC 
and an increase in the survival rate. A new 
modality based on GHRH antagonists also 
appears to be useful for the treatment of 
metastatic CRPC.
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Table 1: Structure of growth hormone‑releasing hormone antagonist, MIA‑602
Chemical structure of MIA-602
MIA‑602 [(PhAc‑Ada)0‑Tyr1, D‑Arg2, Phe (F)5
6, Ala8, Har9, Tyr (Me)10, His11, Orn12, Abu15, His20, Orn21, Nle27, 
D‑Arg28, Har29] hGH‑RH (1‑29) NH2
Abu: alpha‑aminobutyric acid; Ada: 12‑aminododecanoyl; Har: homoarginine; Nle: norleucine; Orn: ornithine; 
PhAc: phenylacetyl; Tyr (Me): O‑methyltyrosine; Ac: acetyl; Agm: agmatine; Amc: 8‑aminocaprylyl; 
Amp: para‑amidino‑phenylalanine; Oct: octyl; Tyr (Et): O‑ethyltyrosine; Ibu: isobutyryl
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